cabozantinib s-malate
cabozantinib s-malate: sourced relationships with 1 company · 13 clinical trials tracked · 2 FDA decisions.
cabozantinib s-malate evidence translation
What we can confirm
2 FDA records · 13 tracked trials
What it means
What to watch
Prepared research question
How could cabozantinib s-malate → EXEL affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| EXELIXIS, INC. (EXEL) Progressive, metastatic medullary thyroid cancer (MTC) | Approved |
Clinical Trial Registry Records (13)showing 10 most recent
A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)
Primary endpoint: Dose-limiting toxicities and incidence of adverse events
Phase II Open Label, Single-Arm Study of Cabozantinib in Combination With Pembrolizumab in the Treatment of Locally Advanced or Metastatic Adrenocortical Carcinoma
Primary endpoint: Overall response rate (ORR)
Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
Primary endpoint: Progression-free survival (PFS)
A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Primary endpoint: Progression free survival
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Primary endpoint: Occurrence of dose-limiting toxicity (Feasibility)
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Primary endpoint: Biomarker results turnaround time
A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma
Primary endpoint: Recurrence free survival (RFS)
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
Primary endpoint: Overall survival (OS)
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
Primary endpoint: Incidence of dose limiting toxicities (DLTs)
A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination With Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Primary endpoint: Incidence of adverse events
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with cabozantinib s-malate?
cabozantinib s-malate has dated SEC/FDA relationship records for EXELIXIS, INC..
How many clinical trials involve cabozantinib s-malate?
BioSniper tracks 13 clinical trials involving cabozantinib s-malate.
What is cabozantinib s-malate's latest FDA decision?
The most recent tracked FDA decision for cabozantinib s-malate is Approval for 1 INDICATIONS AND USAGE CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab ( 1.1 ) patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.2 ) adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progress, dated April 25, 2016.